iQure Pharma Raises $600K in Early Closing of Series A
- iQure Pharma, a Princeton, NJ-based biotech company, raised $600K in Early Closing as part of its Series A funding
- The round was led by Keiretsu Mid-Atlantic, together with business angels associated with Keiretsu’s Accelerator Fund and the Keiretsu North-West chapter
- The company intends to use the funds for research into neuropathic pain compounds
- iQurePharma is focused on the development of therapeutics for neuropathic pain, epilepsy, and wider neurodegenerative diseases
- The company aims to advance the preclinical development novel therapeutics iQ-007 and iQ-008
- In particular, iQ-007 has demonstrated positive results in NIH ETSP tests, which show that the compound has the ability to treat pain, epilepsy, and potentially neurodegenerative diseases
